MannKind (NASDAQ:MNKD) is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics for patients with diseases that require high patient adherence and novel delivery methods. The company’s proprietary Technosphere® platform enables rapid systemic delivery of therapeutic molecules via inhalation, with its lead product, Afrezza®, positioned as the first and only inhaled insulin approved by the U.S. Food and Drug Administration for the treatment of adults with type 1 and type 2 diabetes. Headquartered in Westlake Village, California, MannKind operates research and manufacturing facilities in the United States and partners with international distributors to extend its global reach.
Founded in 1991 by entrepreneur and philanthropist Dr. Alfred E. Mann, MannKind originally focused on innovative drug delivery technologies and was rebranded as MannKind Corporation in 2010. The company navigated complex clinical development and regulatory pathways before securing FDA approval for Afrezza in 2014. In the years following approval, MannKind has refined its commercial infrastructure, established strategic collaborations and optimized manufacturing processes to support the consistent supply of its inhaled insulin therapy.
In addition to its marketed therapy, MannKind maintains a robust research and development pipeline exploring the application of its inhalation platform for pulmonary delivery of therapeutic peptides, proteins and small molecules. Ongoing programs target areas such as immuno-oncology and metabolic disorders, with preclinical and clinical studies assessing the safety and efficacy of next-generation formulations. Strategic partnerships with academic institutions and specialty biopharma companies have broadened MannKind’s scientific reach and may accelerate the translation of its platform into new therapeutic areas and international markets.
The company’s leadership team is headed by President and Chief Executive Officer Matthew Pfeffer, who joined MannKind in 2019 and brings more than two decades of experience in commercial strategy and product development within the pharmaceutical industry. Under Pfeffer’s stewardship, the organization continues to optimize its commercial footprint, pursue innovation through its Technosphere platform and explore licensing arrangements to drive long-term growth and deliver value to patients, healthcare providers and shareholders.
